promoters. The genetic pathway leading to MSI-L is unknown, although higher levels of promoter methylation are observed in this group compared with MSS CRCs. This study explored how promoter methylation affects MSI phenotype, by analysing the methylation status of eight CRC-related promoters, MSI phenotype and KRAS/BRAF mutations in a series of 234 CRCs. Promoter methylation of p14 ARF was significantly related to MSI-L CRC with KRAS mutation. The MSI-H phenotype was related to methylation of MLH1 as expected, while the MSS phenotype was related to methylation of p16 INK4a and O 6methylguanine-DNA methyltransferase, although this was not statistically significant. Thus, promoter methylation of p14 ARF could be a significant alteration leading to CRC with MSI-L.
Introduction
Microsatellite instability (MSI) is a phenomenon observed in a subset of hereditary and sporadic colorectal cancers (CRCs) with mismatch repair (MMR) deficiency. Germline mutations in one of the MMR genes, including MLH1, MSH2, MSH6 and PMS2, have been revealed as the responsible alterations in Lynch syndrome. 1 The MSI-H is also observed in 10 -15% of sporadic CRCs and this phenomenon is caused by promoter methylation of MLH1. 2, 3 MSI has been classified into two categories, high-level MSI (MSI-H) and low-level MSI (MSI-L), differentiated by the frequency of unstable MSI markers among the total number of markers examined. 4 A subset of CRCs showing MSI-L has not been explained by any causative genetic or epigenetic alterations and remains ambiguous.
Both hereditary and sporadic MSI-H CRCs show distinct clinicopathological features K Kominami, T Nagasaka, HM Cullings et al. p14 methylation is related to MSI-L colorectal cancer from other CRCs, such as the development of more cancers in the right side of the colon, having mucinous or poorly differentiated pathological features and showing better prognosis. 5, 6 On the other hand, clinicopathological features of MSI-L CRC are not well defined. Moreover, there has been controversy over the authenticity of a MSI-L phenotype, because molecular distinctiveness separating MSI-L from microsatellite stable (MSS) cancers has not been shown. 7 In terms of MSI markers, MSI-H CRCs -especially those caused by mutation of MLH1 or MSH2 -show frequent instability in mononucleotide markers such as BAT 25 and BAT 26, 4, 8, 9 and specific diagnostic markers for MSI-L have not been elucidated. Nevertheless, certain molecular features are distributed on a non-random basis within the non-MSI-H subset of CRCs. The study by Halford et al. 10 distinguished a 'true-MSI-L' group, a 'super-stable' group and an intermediate group with very mild background within the non-MSI-H group. Laiho et al. 11 claimed the overall mutation rate in MSI-L cancers was equivalent to that of normal human fibroblasts and that microsatellite mutations would accumulate merely on a stochastic basis. However, distinction between the intermediate group and the super-stable group was observed in their study by the use of very numerous, relatively stable markers. Although a panel of MSI-L markers has been selected by trial and error, commonly used markers, including the National Cancer Institute's panel of markers, 4 are still relatively insensitive for picking up MSI-Ls (compared with mononucleotide markers for MSI-Hs) and, when ideal MSI-L markers were used, approximately 20% of advanced CRCs were generally designated as MSI-L. 12 Although causative alteration of the MSI-Ls has not been fully discovered, there are several candidates. Promoter methylation of O 6 -methylguanine-DNA methyltransferase (MGMT) could be a candidate for MSI-L. Theoretically, a defect of MGMT causes MSI-L, because loss of MGMT could allow a dinucleotide microsatellite for slippage. It has also been shown that loss of heterozygosity (LOH) of MYCL may be related to the MSI-L phenotype of CRC. 13 More recently, epigenetic alteration has emerged as a key molecular event in carcinogenesis. Promoter methylation is considered as an important causative alteration in carcinogenesis and several responsible promoters have been elucidated. 14 On the other hand, mutations of KRAS and BRAF are also important early events in colorectal carcinogenesis, and we and other groups have shown that alterations of BRAF and KRAS are strongly correlated with the level of methylation in multiple promoters in CRC. 14 Among the genes whose methylation is involved in colorectal carcinogenesis, some may be related to the phenotypic expression of MSI-L, just as methylation of MLH1 is related to the phenotype of the sporadic MSI-H CRC.
The aim of this study was to explore differences in methylation status of promoters between MSI-L and non-MSI-L (MSI-H and MSS) CRC, to elucidate the causative alteration for the MSI-L phenotype of CRC. 15 Samples of both tumour and normal mucosal tissue were stored at -80°C and DNA was extracted by the standard procedure involving digestion with proteinase K and phenol-chloroform extraction. 16 
Patients and methods

PATIENT TISSUE SAMPLES
DETECTION OF BRAF CODON 600, AND KRAS CODON 12 AND 13 MUTATIONS
The BRAF codon 600 mutation was assessed by the restriction fragment length polymorphism-polymerase chain reaction (RFLP/PCR) approach as previously reported. 14 To detect KRAS codon 12 and 13 mutations, a modified artificial RFLP/PCR approach was used. 17 All products were visualized on 3% agarose gels stained with ethidium bromide. The nature of each mutation detected by RFLP analysis was confirmed by sequencing the appropriate DNA samples in a SQ-5500E autosequencer (Hitachi, Tokyo, Japan) used in accordance with the manufacturer's instructions.
BISULPHITE MODIFICATION AND DETECTION OF METHYLATION STATUS OF MULTIPLE LOCI
Sodium bisulphite modification was performed using a CpGenome DNA Modification Kit (Intergen, New York, NY, USA). The methylation status of MINT1 (methylation in tumour gene), MINT2, MINT31, CACNA1G, p16 INK4a and p14 ARF was evaluated and determined by combined bisulphite restriction analysis (COBRA) using previously described procedures. 18 -20 The methylation status of MLH1 (3′ region of the MLH1 promoter) and MGMT was determined by methylation-specific single PCR as previously described. 14 A subset of CRC has been known to accumulate methylation in promoters and was classified in terms of a CpG island methylator phenotype (CIMP), which can be identified by the frequent methylation of CIMP markers. 21 In this study, tumours were classified as CIMP if more than two out of five markers (MINT1, MINT2, MINT31, p16 INK4a and MLH1) showed methylation. 21
MICROSATELLITE ANALYSIS
The MSI testing for each tumour was determined on the basis of an examination of 12 microsatellite markers (BAT25, BAT26, BAT40, D2S123, D5S107, D5S346, D8S87, D17S261, D17S250, D18S35, D18S58 and MYCL1) as previously described. 13 Tumours were classified as MSI-L and MSI-H, if < 40% and ≥ 40% of the markers displayed MSI, respectively. Tumours displaying no MSI with any of the microsatellite markers that were tested were classified as MSS.
STATISTICAL ANALYSIS
All statistical analyses were performed using JMP4.05J software (SAS ® Institute Inc., Cary, NC, USA). Differences in frequencies were evaluated by the Fisher's exact test or Pearson's χ 2 test where appropriate. The association between methylation status of promoters and tumour classification in each of three CRC subsets, in contrast to tumours with no mutation (neither BRAF nor KRAS), was determined using a logistic regression on the methylation status of individual tumours at each of the promoter loci. In these logistic regressions, the methylation status of each locus for a given tumour was a binary variable (0, not methylated; 1, methylated) and the outcome variable was a binary indicator variable for each subtype versus wild type, i.e. 0, neither mutation; 1, BRAF or p14 methylation is related to MSI-L colorectal cancer KRAS/MSI-L or KRAS/MSS, as applicable. Logistic regression models were obtained by stepwise backward selection beginning with all promoter regions as candidate variables. All reported P-values are two-sided and a Pvalue ≤ 0.05 was considered statistically significant.
Results
The tumour tissues and samples of corresponding normal mucosa were obtained from 234 CRC patients who had undergone curative surgery.
MSI STATUS IN CIMP AND NON-CIMP CRCs WITH EITHER BRAF OR KRAS MUTATION
DNA methylation is one of the key events in colorectal carcinogenesis after initiating mutations of KRAS, BRAF and APC. 14 It has already been shown that CRC with neither BRAF nor KRAS mutations has a low frequency of promoter methylation. 14 Accordingly in this study, the methylation status of multiple promoters was compared with MSI status within a series of CRC with either a BRAF or KRAS mutation (93 cases). Table 1 shows the distribution of MSI status: these results indicate that MSI-H was associated with CIMP and MSS was associated with non-CIMP (P < 0.001, χ 2 test). Interestingly, among the CRCs with either BRAF or KRAS mutations, the incidence of MSI-L between CIMP and non-CIMP CRCs showed no significant difference (Table 1) .
METHYLATION STATUS IN RELATION TO BRAF/KRAS MUTATION AND/OR MSI STATUS
As previously shown, 14 CRCs with the BRAF mutation showed high frequency methylation in a range from 76% to 95% among the five CIMP markers (MINT1, MINT2, MINT31, p16 INK4a and MLH1; Table 2 ). CRCs with the KRAS mutation had less methylation, ranging from 0% to 33%, among the five CIMP markers and CRCs with neither a KRAS nor BRAF mutation had very little methylation, ranging from 0% to 13%, among the five CIMP markers. Most of the CRCs with the BRAF mutation were consistent with MSI-H cancers (16/21, 76.2%) and showed frequent promoter methylation in CIMP genes. In contrast, most CRCs with neither BRAF nor KRAS mutations were consistent with MSS cancers (88/141; 62.4%) and
showed infrequent promoter methylation in CIMP genes. Nevertheless, CRCs with the KRAS mutation were consistent with either MSI-L (24/67; 35.8%) or MSS (43/67; 64.2%) and showed a methylation frequency between those with a BRAF mutation and those with neither mutation. Thus, a possible differentiating factor for the MSI-L phenotype was identified among the CRC with KRAS mutations. As shown in Table   TABLE 1 
: Distribution of MSI status in 32 CpG island methylator phenotype (CIMP) a and 61 non-CIMP colorectal cancers with either a BRAF b or KRAS mutation
MSI-H (%) MSI-L (%) MSS (%) P-value
METHYLATION STATUS OF MULTIPLE PROMOTERS VS BRAF/KRAS MUTATION AND MSI STATUS IN WHOLE SAMPLES
A series of logistic regressions were performed on the methylation status of the eight promoters in Table 2 to evaluate which promoters provided the most information for distinguishing tumours with the BRAF mutation from those with neither mutation, KRAS/MSI-L from those with neither mutation, and KRAS/MSS from those with neither mutation ( Table 3 ). The best logistic regression models included: MINT1, MINT2 and MLH1 for BRAF; MINT2 and p14 ARF for KRAS/MSI-L; and MINT2, p16 INK4a and MGMT for KRAS/MSS (Table 3 ). This multivariate analysis supports the idea that, among CRCs with the KRAS mutation, MSI-L cancer develops through the methylation of p14 ARF and that many of the MSS CRCs are associated with methylation of p16 INK4a .
Discussion
Three initiation events occur in the early neoplastic lesions of colorectal carcinogenesis, comprising mutations of BRAF, KRAS and APC. 22 Dysplastic aberrant crypt foci (ACF) are considered to be the earliest identifiable lesions of the traditional adenoma-carcinoma pathway for development of CRC. 23 KRAS mutation is often observed in ACF and could be initiated by inhibition of apoptosis through the KRAS mutation. 23 However, ACF is a common lesion and the vast majority probably do not progress to small adenomas. Early mutation of APC would provide one mechanism for initiating conversion of ACF to adenoma. The traditional adenoma-carcinoma progression sequence is supported by substantial evidence that mutations, such as KRAS and TP53, lead to the development of CRCs with MSS or MSI-L. 23 More recently, an alternative pathway has been proposed based on the progression from colonic lesions with serrated morphology. 24 Possible pre-malignant lesions for sporadic MSI-H CRC are now attributed to sessile serrated adenoma (SSA), a variant hyperplastic polyp, which may progress to the sporadic MSI-H CRC through the serrated-neoplastic pathway. 25 Frequent mutation of BRAF (V600E), which is commonly identified in sporadic MSI-H CRC, has already been observed in SSA and even in the earlier serrated hyperplastic ACF. 26 -28 Such serrated lesions, initiated by the mutation of BRAF, start accumulating methylation in multiple gene promoters such as p16 INK4a and MLH1. 26, 29 Thereafter, the majority of SSAs with BRAF mutations eventually acquire methylation at the 3′ site of the MLH1 promoter and these neoplastic lesions may progress to MSI-H CRC (Nagao A, et al. unpublished). Interestingly, methylation at the 3′ site of the MLH1 promoter is never observed in sporadic CRCs with KRAS mutations. 14 A subset of early lesions with KRAS mutations may also begin accumulation of promoter methylation in several genes. 30 MGMT is one of these genes and silencing of MGMT by promoter methylation causes G to A transition mutations in several cancer-related genes such as KRAS and TP53. 31, 32 Methylation of MGMT was a frequent alteration observed in the subset of CRC with both MSI-L status and KRAS mutation. 14 Although MSI-L type CRC is not fully understood, in the present study it was possible to show that the KRAS/MSI-L CRCs differed from KRAS/MSS CRCs in having frequent promoter methylation in p14 ARF , confirmed by multivariate analysis. Among the cancer-related gene promoters examined, the best regression model for BRAF (thus MSI-H) CRC was MLH1, that for KRAS/MSI-L CRC was p14 ARF and that for KRAS/MSS CRC was MGMT and p16 INK4a since the MINT genes are not confirmed as cancercausing. Given that p14 ARF has been proposed as a key molecular alternative for TP53 in colorectal carcinogenesis, 20, 33, 34 it can be speculated that methylation of p14 ARF may facilitate in progression to MSI-L CRC without mutation of TP53. Alternatively, TP53 mutations followed by the methylation of MGMT on pre-malignant lesions initiated by a KRAS mutation may facilitate progression to the MSS phenotype. 14 In conclusion, differing pathways of colorectal carcinogenesis have been gradually elucidated. Adenomatous or serrated ACF are proposed as precursors to advanced colonic neoplasms initiated by KRAS, BRAF or APC mutations. Promoter methylation occurring in multiple cancerrelated genes followed by these events is an important step in determining the direction of progression to one of the CRC subtypes. Since methylation of MLH1 is the key event for the sporadic occurrence of MSI-H CRC, it is possible that methylation of p14 ARF could be pivotal to progression to the MSI-L subtype of CRC, even though the MSI-L phenotype is still ambiguous.
